Clover Health Investments (CLOV) Cash & Equivalents (2019 - 2026)

Clover Health Investments (CLOV) has 8 years of Cash & Equivalents data on file, last reported at $173.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 11.47% year-over-year to $173.3 million; the trailing twelve-month figure through Mar 2026 stood at $173.3 million (up 11.47% YoY), and the FY2025 full-year result was $78.3 million, down 59.75% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $173.3 million, up from $78.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $382.9 million in Q3 2022 and bottomed at $78.3 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $194.5 million (2024), against an average of $219.9 million.
• Peak annual rise in Cash & Equivalents reached 664.91% in 2022, while the deepest fall reached 65.4% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $103.8 million in 2022, then increased by 18.38% to $122.9 million in 2023, then jumped by 58.34% to $194.5 million in 2024, then sank by 59.75% to $78.3 million in 2025, then surged by 121.28% to $173.3 million in 2026.
• The last three Cash & Equivalents figures came in at $173.3 million (Q1 2026), $78.3 million (Q4 2025), and $190.1 million (Q3 2025), per Business Quant data.

Peer Comparison